Assenagon Asset Management S.A. Aurinia Pharmaceuticals Inc. Transaction History

Assenagon Asset Management S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 15, 2021	SELL	$10.0 - $14.52 $1.12 Million - $1.63 Million	-112,448 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$12.3 - $18.73 $1.38 Million - $2.11 Million	112,448 New	112,448 $1.46 Million
Q4 2020 Feb 01, 2021	SELL	$12.94 - $16.05 $3.11 Million - $3.86 Million	-240,455 Closed	0 $0
Q3 2020 Oct 07, 2020	SELL	$13.19 - $16.66 $8.64 Million - $10.9 Million	-655,317 Reduced 73.16%	240,455 $3.54 Million
Q2 2020 Jul 21, 2020	SELL	$14.12 - $18.33 $1.46 Million - $1.89 Million	-103,072 Reduced 10.32%	895,772 $14.6 Million
Q1 2020 Apr 17, 2020	BUY	$11.34 - $21.46 $11.3 Million - $21.4 Million	998,844 New	998,844 $14.5 Million

207

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.27B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.